Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK1 | Q13464 | 12/20 | 0.63 |
| ▸ | RPS6KA5 | O75582 | 3/20 | 0.56 |
| ▸ | RPS6KB1 | P23443 | 6/20 | 0.55 |
| ▸ | GSK3B | P49841 | 2/20 | 0.55 |
| ▸ | PRKACA | P17612 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4000688 | 0.92 | ROCK1 (0.65) | ROCK1RPS6KA5RPS6KB1GSK3BPRKACA | |
| SCHEMBL3997136 | 0.91 | ROCK1 (0.54) | ROCK1RPS6KA5RPS6KB1GSK3BPRKACA | |
| Hydrochloric Acid SCHEMBL4716613 | 0.90 | ROCK1 (0.59) | ROCK1RPS6KA5RPS6KB1GSK3BPRKACA | |
| SCHEMBL3999484 | 0.89 | RPS6KA5 (0.59) | ROCK1RPS6KA5RPS6KB1GSK3BPRKACA | |
| SCHEMBL4000422 | 0.86 | ROCK1 (0.70) | ROCK1RPS6KA5RPS6KB1GSK3BPRKACA | |
| SCHEMBL4718662 | 0.85 | ROCK1 (0.53) | ROCK1RPS6KA5RPS6KB1GSK3BPRKACA | |
| SCHEMBL4001844 | 0.85 | ROCK1 (0.53) | ROCK1RPS6KA5RPS6KB1GSK3BPRKACA | |
| SCHEMBL4000466 | 0.85 | ROCK1 (0.50) | ROCK1RPS6KA5RPS6KB1GSK3BPRKACA | |
| SCHEMBL4001614 | 0.84 | ROCK1 (0.54) | ROCK1RPS6KA5RPS6KB1GSK3BPRKACA | |
| Hydrochloric Acid SCHEMBL4715344 | 0.84 | ROCK1 (0.52) | ROCK1RPS6KA5RPS6KB1GSK3BPRKACA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7547779-B2 | Preparation of 1,6-disubstituted azabenzimidazoles as kinase inhibitors | GLAXO GROUP LIMITED (GB) | 2009-06-16 | — | — | US | claimed |
| US-20080234261-A1 | Preparation of 1,6-Disubstituted Azabenzimidazoles as Kinase Inhibitors | GLAXOSMITHKLINE LLC | 2008-09-25 | — | — | US | claimed |
| US-7547779-B2 | Preparation of 1,6-disubstituted azabenzimidazoles as kinase inhibitors | GLAXO GROUP LIMITED (GB) | 2009-06-16 | — | — | US | disclosed |
| EP-1675552-A4 | PREPERATION OF 1,6-DISUBSTITUTED AZABENZIMIDAZOLES AS KINASE INHIBITORS | GLAXO GROUP LTD (GB) | 2009-06-03 | — | — | EP | disclosed |
| US-20080234261-A1 | Preparation of 1,6-Disubstituted Azabenzimidazoles as Kinase Inhibitors | GLAXOSMITHKLINE LLC | 2008-09-25 | — | — | US | disclosed |
| EP-1675552-A2 | PREPERATION OF 1,6-DISUBSTITUTED AZABENZIMIDAZOLES AS KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2006-07-05 | — | — | EP | disclosed |
| WO-2005037197-A2 | PREPERATION OF 1,6-DISUBSTITUTED AZABENZIMIDAZOLES AS KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2005-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080234261-A1 | Preparation of 1,6-Disubstituted Azabenzimidazoles as Kinase Inhibitors | TNK2, ROCK1, ARHGDIB | ROCK1 2/4885RPS6KA5 99/4885RPS6KB1 97/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.